Haleon Pakistan Limited (PSX: HALEON) has made waves in the pharmaceutical industry with its recent announcement of a significant investment of approximately $10 million in its manufacturing facility based in Jamshoro. The aim of this substantial financial commitment is to bolster the production of its widely recognized Panadol base portfolio, encompassing the popular Panadol 500mg and Panadol Extra tablets. In a recent disclosure to the Pakistan Stock Exchange, the company highlighted its mission to introduce state-of-the-art manufacturing technology in Pakistan, a move that is anticipated to escalate the production capacity to an impressive 8 billion tablets.
This strategic investment comes as part of Haleon Pakistan’s unwavering dedication to ensuring a seamless and uninterrupted supply of essential pharmaceutical and over-the-counter medications to meet the needs of patients and consumers across the nation. Notably, the company has also allocated an additional $2 million to fortify its manufacturing capabilities for its flagship product, CaC 1000 Plus. This investment is strategically aligned to cater to the burgeoning local demand while simultaneously exploring new export opportunities.
The resolute approval of this transformative investment and its associated financial arrangements by the Board of Directors of Haleon Pakistan Limited underscores the company’s commitment to advancing its manufacturing capabilities and its unwavering dedication to contributing to the advancement of the healthcare sector. As a subsidiary of Haleon Netherlands B.V. and operating under the umbrella of Haleon plc, the company remains steadfast in its mission to manufacture, market, and distribute consumer healthcare and over-the-counter health products, with a continued commitment to innovation and excellence.
